Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Vascular Biogenics Pretax Margin % Related Terms
Vascular Biogenics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Vascular Biogenics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0VB vs MBIO, GNPX, LEXX: Pretax Margin % Comparison
For the Biotechnology subindustry, Vascular Biogenics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vascular Biogenics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Vascular Biogenics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vascular Biogenics (STU:0VB) has a Pretax Margin % of % as of Jun. 2023. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Vascular Biogenics and its competitors.
Is Vascular Biogenics' Pretax Margin % too high?
Vascular Biogenics' current Pretax Margin % is %. Overall, Vascular Biogenics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Vascular Biogenics' Pretax Margin % compare to MBIO and GNPX?
Vascular Biogenics' Pretax Margin % of % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Vascular Biogenics and its competitors. Vascular Biogenics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vascular Biogenics stock overvalued right now?
Vascular Biogenics (STU:0VB) has a current Pretax Margin % of %. The current Pretax Margin % is %. Vascular Biogenics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Vascular Biogenics (STU:0VB), the current Pretax Margin % is % as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0VB has been successfully added to your 
